Beyond repair: engineered tissue that the body accepts as its own.
Cell home® is our tissue-engineering platform — the long-term answer to the global shortage of transplantable tissue. By building consistent, functional human tissue in-vitro and supporting in-vivo regeneration, we aim to eliminate donor-site morbidity and the ethics of donor scarcity.
From "patch the wound" to "grow the tissue".
Today's standard of care for tissue loss is autologous grafting: take tissue from one site, move it to another. This creates a second wound, increases surgical risk, and is limited by what the patient has available.
Cell home® replaces this with engineered tissue. We use autologous or allogeneic cells, scaffold them in the right 3D architecture, mature them under controlled conditions, and deliver a transplant-ready tissue with the patient's biology built in.
The end-state: consistent, functional tissue available on demand, without donor site morbidity and without the ethics of donor scarcity.
From bone to neural. A platform with broad reach.
Cell home® is indication-agnostic. Our current internal R&D pipeline targets five high-value areas.
Three things that change the equation.
① Integrated manufacturing
Cell home® runs on the same 3D-printing backbone as ME-Fab® — patient-specific geometry is a built-in capability, not an add-on.
② Coupled release
ME-Regen® integration means our engineered tissues carry their own sustained-release regenerative signals. No bolus dosing, no rapid washout.
③ Real-world evidence base
500+ hospital clinical relationships and 5,000+ implant cases provide a feedback loop for tissue-engineering design refinements.
Where Cell home® is today.
Core R&D is complete. Pilot scale-up and pre-clinical work are the immediate next steps.
Core R&D closed-loop
Cell sourcing, scaffold fabrication, bioreactor design, and release criteria validated in vitro.
Pilot scale-up
GMP-compatible pilot manufacturing line in progress. Co-located with Phase II expansion.
Pre-clinical & clinical
Pre-clinical animal studies and first-in-human studies planned. IND/CTA filings targeted for 2027–2028.
Build the future of tissue repair with us.
Cell home® is built for long-term partnership. Whether you're a research institution, a strategic investor, or a clinical centre, let's explore the possibilities together.